SCHEMBL3569907

SCHEMBL3569907

CN(C)Cc1ccccc1-c1ccc(NC(=O)C(c2ccccc2F)N(C(N)=O)c2ccc(Cl)cc2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F10 P00742 11/20 0.47
F2 P00734 2/20 0.47
KLK1 P06870 1/20 0.47
P2RY1 P47900 2/20 0.43
KCNH2 Q12809 1/20 0.43
F5 P12259 1/20 0.40
CTRB1 P17538 1/20 0.40
FPR1 P21462 1/20 0.38
FPR2 P25090 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LIMK1 P53667 2/20 0.36
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34
PRSS1 P07477 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567712 0.93 P2RY1 (0.44) F10F2KLK1P2RY1KCNH2
SCHEMBL3570559 0.89 F10 (0.41) F10F2KLK1P2RY1KCNH2
SCHEMBL3559106 0.80 F10 (0.43) F10F2KLK1MEN1MAPT
SCHEMBL3569909 0.79 F10 (0.48) F10F2KLK1P2RY1KCNH2
SCHEMBL3564154 0.79 F10 (0.50) F10F2KCNH2F5CTRB1
SCHEMBL3557259 0.72 HDAC4 (0.44) MEN1MAPTKMT2A
SCHEMBL3567714 0.72 P2RY1 (0.46) F10F2KLK1P2RY1KCNH2
SCHEMBL3570293 0.71 GAA (0.36) KLK1MEN1MAPTKMT2A
SCHEMBL3570562 0.70 UTS2R (0.44) F10F2KLK1P2RY1KCNH2
SCHEMBL3569300 0.69 CNR2 (0.41) MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 F10 9/4885F2 6/4885KLK1 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.